Abhinav Deol, MD

Articles

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Dr Deol on Sequencing Treatment Options With CAR T-Cell Therapy in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

Dr Deol on CAR T-cell Therapy Selection for Patients With Relapsed/Refractory Myeloma

April 12th 2023

Abhinav Deol, MD, discusses the selection of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Dr Deol on CAR T-cell Therapy in Multiple Myeloma

April 7th 2023

Abhinav Deol, MD, discusses the efficacy and durability of CAR T-cell therapies in patients with multiple myeloma.

Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma

March 22nd 2023

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

August 20th 2022

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

May 20th 2022

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.

Dr. Deol on CAR T-Cell Therapy in Earlier Lines of Therapy in Cancer Care

May 3rd 2022

Abhinav Deol, MD, discusses shifting CAR T-cell therapy to earlier lines of therapy in cancer care.

Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

October 8th 2020

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Dr. Deol on the Utility of Tisagenlecleucel in ALL

October 7th 2020

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia

September 22nd 2020

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

Dr. Deol on the Approval of Brexucabtagene Autoleucel in MCL

September 17th 2020

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia

November 17th 2018

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Dr. Deol on the Safety of CAR T-Cell Therapy

September 28th 2018

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.